- Home
- DCOM vs ATAI Comparison
DCOM vs ATAI Comparison
Compare DCOM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCOM | ATAI |
|---|---|---|
| Founded | 1864 | 2018 |
| Country | United States | United States |
| Employees | 902 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | DCOM | ATAI |
|---|---|---|
| Price | $39.98 | $4.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $37.80 | $15.88 |
| AVG Volume (30 Days) | 352.1K | ★ 10.1M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $21.40 | N/A |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | $14.81 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $25.63 | $2.58 |
| 52 Week High | $41.62 | $6.73 |
Technical Indicators
Market Signals| Indicator | DCOM | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 54.59 |
| Support Level | $38.47 | $3.56 |
| Resistance Level | $41.19 | $5.00 |
| Average True Range (ATR) | 0.97 | 0.43 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 50.75 | 62.50 |
Price Performance
Historical ComparisonAbout DCOM Dime Community Bancshares Inc.
Dime Commercial Bancshares Inc is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.